EGFR and gastric cancer: Oshima and co-workers demonstrated that, in mouse models of gastric cancer, the expression levels of EGFR ligands (i.e., epiregulin, amphiregulin, heparin-binding EGF-like growth factor, and betacellulin), and metalloproteinases are increased in a PGE2-pathway-dependent manner.